Nazione: Stati Uniti
Lingua: inglese
Fonte: NLM (National Library of Medicine)
ZOLPIDEM TARTRATE (UNII: WY6W63843K) (ZOLPIDEM - UNII:7K383OQI23)
DIRECT RX
ZOLPIDEM TARTRATE
ZOLPIDEM TARTRATE 12.5 mg
ORAL
PRESCRIPTION DRUG
Zolpidem tartrate extended-release tablets, USP are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration[see CLINICAL STUDIES (14)]. - Zolpidem tartrate extended-release tablets are contraindicated in patients with known hypersensitivity to zolpidem. Observed reactions include anaphylaxis and angioedema [see WARNINGS AND PRECAUTIONS (5.3)]. Zolpidem tartrate extended-release tablets are contraindicated in patients with known hypersensitivity to zolpidem. Observed reactions include anaphylaxis and angioedema [see WARNINGS AND PRECAUTIONS (5.3)]. 8.1 Pregnancy Pregnancy Category C There are no adequate and well-controlled studies of zolpidem tartrate extended-release in
Zolpidem tartrate extended-release tablets, USP are available as follows: 6.25 mg, dark pink, round, biconvex film-coated tablets debossed with SZ on one side and 228 on the other side. NDC 0781-5315-31, bottles of 30 tablets NDC 0781-5315-01, bottles of 100 tablets NDC 0781-5315-05, bottles of 500 tablets 12.5 mg, light pink, round, biconvex film-coated tablets debossed with SZ on one side and 229 on the other side. NDC 0781-5316-31, bottles of 30 tablets NDC 0781-5316-01, bottles of 100 tablets NDC 0781-5316-05, bottles of 500 tablets The tablets are to be swallowed whole and should not be crushed, chewed, or divided. Storage Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant, child-resistant container.
Abbreviated New Drug Application
ZOLPIDEM TARTRATE- ZOLPIDEM TARTRATE TABLET, EXTENDED RELEASE DIRECT RX ---------- SPL MEDGUIDE SECTION • MEDICATION GUIDE Zolpidem Tartrate Extended-Release Tablets, USPC-IV (ZOL-pih-dem) Read the Medication Guide that comes with zolpidem tartrate extended-release tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about zolpidem tartrate extended-release tablets? •Do not take more zolpidem tartrate extended-release tablets than prescribed.•Do not take zolpidem tartrate extended-release tablets unless you are able to stay in bed a full night (7 to 8 hours) before you must be active again.•Take zolpidem tartrate extended-release tablets right before you get in bed, not sooner. Zolpidem tartrate extended-release tablets may cause serious side effects that you may not know are happening to you. These side effects include: •sleepiness during the day•not thinking clearly•act strangely, confused, or upset•"sleep-walking" or doing other activities when you are asleep like: eating talking having sex driving a car ∘ ∘ ∘ ∘ Call your healthcare provider right away if you find out that you have done any of the above activities after taking zolpidem tartrate extended-release tablets. You should not drive a car or do things that require clear thinking the day after you take zolpidem tartrate extended-release tablets. Do not take zolpidem tartrate extended-release tablets if you: •drank alcohol that evening or before bed•take other medicines that can make you sleepy. Taking zolpidem tartrate extended-release tablets with other drugs can cause side effects. Talk to your healthcare provider about all of your medicines. Your healthcare provider will tell you if you can take zolpidem tartrate extended-release tablets with your other medicines.•cannot get a full night's sleep What Leggi il documento completo
ZOLPIDEM TARTRATE- ZOLPIDEM TARTRATE TABLET, EXTENDED RELEASE DIRECT RX ---------- ZOLPIDEM TARTRATE INDICATIONS & USAGE SECTION Zolpidem tartrate extended-release tablets, USP are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration[see CLINICAL STUDIES (14)]. DOSAGE & ADMINISTRATION SECTION 2.1 Dosage in Adults Use the lowest effective dose for the patient. The recommended initial dose is 6.25 mg for women and either 6.25 or 12.5 mg for men, taken only once per night immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening. If the 6.25 mg dose is not effective, the dose can be increased to 12.5 mg. In some patients, the higher morning blood levels following use of the 12.5 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see WARNINGS AND PRECAUTIONS (5.1)]. The total dose of zolpidem tartrate extended-release tablets should not exceed 12.5 mg once daily immediately before bedtime. The recommended initial doses for women and men are different because zolpidem clearance is lower in women. 2.2 Special Populations Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate. Patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects. The recommended dose of zolpidem tartrate extended-release tablets in both of these patient populations is 6.25 mg once daily immediately before bedtime [see WARNINGS AND PRECAUTIONS (5.1); USE IN SPECIFIC POPULATIONS (8.5)]. 2.3 Use with CNS Depressants Dosage adjustment may be necessary when zolpidem tartrate extended-release tablets are combined with other CNS depressant drugs Leggi il documento completo